THREE PHASE 1/2, OPEN-LABEL STUDIES OF CEREBLON E3 LIGASE MODULATOR (CELMOD)-BASED REGIMENS IN NEWLY DIAGNOSED (ND) OR RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL)